Literature DB >> 14678197

Impact of cAMP on the T-cell response to type II collagen.

Patricia Ozegbe1, Andrew D Foey, Salman Ahmed, Richard O Williams.   

Abstract

There is considerable interest in the possible use of cAMP-elevating agents in the treatment of autoimmune diseases such as rheumatoid arthritis. The objective of this study was to evaluate the impact of different cAMP-elevating agents on the T-cell response to type II collagen within the context of collagen-induced arthritis, a murine model of rheumatoid arthritis. Spleen cells or lymph node cells from type-II-collagen-immunized DBA/1 mice were cultured in the presence of type II collagen plus one of five different cAMP-elevating agents: rolipram, forskolin, prostaglandin E2, 8-bromo-cAMP, or cholera toxin. Levels of interferon-gamma (IFN-gamma), interleukin-4 (IL-4) and IL-5 were measured in culture supernatants by enzyme-linked immunosorbent assay. All of the cAMP-elevating agents tested were found to profoundly suppress IFN-gamma production in a dose-dependent manner. IL-4 and IL-5 production was slightly up-regulated at low concentrations of the cAMP-elevating agents and was modestly suppressed at the highest concentrations of cAMP-elevating agents. Experiments were then carried out to determine whether T cells were directly affected by cAMP-elevating agents or whether the immunomodulatory effects were mediated via antigen-presenting cells. Pulsing T cells alone for a brief period with cholera toxin produced an almost identical effect to pulsing antigen-presenting cells alone, i.e. down-regulation of proliferation, down-regulation of IFN-gamma production with little effect on IL-5 production. It was concluded that cAMP-elevating agents suppressed T helper type 1 responses to type II collagen to a greater extent than T helper type 2 responses. The cAMP-elevating agents could directly influence the activity of T cells but, in addition, influenced the ability of antigen-presenting cells to support T helper type 1 responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14678197      PMCID: PMC1782387          DOI: 10.1111/j.1365-2567.2004.01768.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

Review 1.  The biological functions of A-kinase anchor proteins.

Authors:  A Feliciello; M E Gottesman; E V Avvedimento
Journal:  J Mol Biol       Date:  2001-04-27       Impact factor: 5.469

2.  Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease.

Authors:  M Delgado; C Abad; C Martinez; J Leceta; R P Gomariz
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

3.  cAMP-elevating agents suppress dendritic cell function.

Authors:  T Kambayashi; R P Wallin; H G Ljunggren
Journal:  J Leukoc Biol       Date:  2001-12       Impact factor: 4.962

4.  Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A.

Authors:  K J Staples; M Bergmann; K Tomita; M D Houslay; I McPhee; P J Barnes; M A Giembycz; R Newton
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

5.  Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action.

Authors:  K J Staples; M Bergmann; P J Barnes; R Newton
Journal:  Biochem Biophys Res Commun       Date:  2000-07-14       Impact factor: 3.575

6.  Pituitary adenylate cyclase-activating polypeptide inhibits collagen-induced arthritis: an experimental immunomodulatory therapy.

Authors:  C Abad; C Martinez; J Leceta; R P Gomariz; M Delgado
Journal:  J Immunol       Date:  2001-09-15       Impact factor: 5.422

7.  Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.

Authors:  J N Francischi; C M Yokoro; S Poole; W L Tafuri; F Q Cunha; M M Teixeira
Journal:  Eur J Pharmacol       Date:  2000-07-07       Impact factor: 4.432

8.  Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression.

Authors:  C H Chen; D H Zhang; J M LaPorte; A Ray
Journal:  J Immunol       Date:  2000-11-15       Impact factor: 5.422

9.  GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells.

Authors:  H J Lee; N Takemoto; H Kurata; Y Kamogawa; S Miyatake; A O'Garra; N Arai
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

10.  Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor.

Authors:  T Vang; K M Torgersen; V Sundvold; M Saxena; F O Levy; B S Skålhegg; V Hansson; T Mustelin; K Taskén
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  7 in total

1.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

Review 2.  Analysing the effect of novel therapies on cytokine expression in experimental arthritis.

Authors:  Richard O Williams; Julia J Inglis; Egle Simelyte; Gabriel Criado; Percy F Sumariwalla
Journal:  Int J Exp Pathol       Date:  2005-10       Impact factor: 1.925

3.  Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo.

Authors:  Jason E Comer; Ashok K Chopra; Johnny W Peterson; Rolf König
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Beta-agonists modulate T-cell functions via direct actions on type 1 and type 2 cells.

Authors:  Matthew J Loza; Susan Foster; Stephen P Peters; Raymond B Penn
Journal:  Blood       Date:  2005-11-08       Impact factor: 22.113

5.  Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen.

Authors:  Julia J Inglis; Gabriel Criado; Mino Medghalchi; Melanie Andrews; Ann Sandison; Marc Feldmann; Richard O Williams
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 6.  Novel Therapeutic Targets in Axial Spondyloarthritis.

Authors:  Claudia Worth; Paul Bowness; M Hussein Al-Mossawi
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-04-12

Review 7.  Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions.

Authors:  Marianna Szczypka
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.